The Traderszone Network

Published in TZ Latest News 2 November, 2016 by The TZ Newswire Staff

Gilead Sciences Inc. Hepatitis C Sales Sink Again in Q3

It’s been a while since Gilead Sciences (NASDAQ: GILD) provided a pleasant surprise for investors with its quarterly earnings. The big biotech announced its third-quarter results after the market closed on Tuesday. Did Gilead turn the corner? Here’s what you need to know about the company’s results.

Scientists And Monitor

Image source: Getty Images.

read more